Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Gets Price Target Bump from Robert W. Baird

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target hoisted by equities research analysts at Robert W. Baird from $761.00 to $875.00 in a research report issued on Monday, Benzinga reports. The firm presently has a “neutral” rating on the biopharmaceutical company’s stock. Robert W. Baird‘s target price would suggest a potential downside of 5.70% from the stock’s previous close.

REGN has been the topic of several other reports. Guggenheim boosted their price objective on shares of Regeneron Pharmaceuticals from $1,000.00 to $1,030.00 and gave the company a “buy” rating in a report on Monday, August 3rd. Zacks Research upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Monday, September 28th. BMO Capital Markets boosted their price objective on shares of Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the stock an “outperform” rating in a research report on Wednesday, September 9th. Raymond James Financial increased their price objective on Regeneron Pharmaceuticals from $902.00 to $911.00 and gave the company an “outperform” rating in a report on Friday, July 31st. Finally, Sanford C. Bernstein lifted their target price on Regeneron Pharmaceuticals from $753.00 to $756.00 and gave the company a “market perform” rating in a research note on Friday, August 14th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and eight have given a Hold rating to the stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $872.00.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ:REGN opened at $927.89 on Monday. The company has a market cap of $95.54 billion, a PE ratio of 20.49, a price-to-earnings-growth ratio of 1.57 and a beta of 0.10. Regeneron Pharmaceuticals has a twelve month low of $591.52 and a twelve month high of $935.35. The company’s 50 day moving average is $793.30 and its 200 day moving average is $738.05. The company has a current ratio of 4.06, a quick ratio of 3.66 and a debt-to-equity ratio of 0.08.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Friday, October 30th. The biopharmaceutical company reported $20.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $16.51 by $3.56. Regeneron Pharmaceuticals had a net margin of 28.51% and a return on equity of 16.01%. The company had revenue of $5.12 billion during the quarter, compared to analysts’ expectations of $4.58 billion. During the same quarter in the prior year, the company earned $11.83 EPS. Regeneron Pharmaceuticals’s revenue was up 36.3% compared to the same quarter last year. On average, sell-side analysts forecast that Regeneron Pharmaceuticals will post 49.10 EPS for the current year.

Insider Activity

In other news, Director Kathryn Guarini sold 400 shares of the stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total value of $340,000.00. Following the completion of the sale, the director directly owned 603 shares of the company’s stock, valued at approximately $512,550. This represents a 39.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Y. Zoghbi sold 800 shares of the firm’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $800.00, for a total value of $640,000.00. Following the completion of the transaction, the director directly owned 1,703 shares of the company’s stock, valued at approximately $1,362,400. This trade represents a 31.96% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 8,093 shares of company stock valued at $6,506,845. 6.97% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Western Wealth Management LLC acquired a new position in Regeneron Pharmaceuticals during the 1st quarter worth about $26,000. Armstrong Advisory Group Inc. lifted its holdings in Regeneron Pharmaceuticals by 466.7% during the 3rd quarter. Armstrong Advisory Group Inc. now owns 34 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 28 shares in the last quarter. Activest Wealth Management boosted its position in Regeneron Pharmaceuticals by 780.0% in the 3rd quarter. Activest Wealth Management now owns 44 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 39 shares during the last quarter. Alpine Bank Wealth Management bought a new position in Regeneron Pharmaceuticals in the 3rd quarter valued at $34,000. Finally, Mowery & Schoenfeld Wealth Management LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at $29,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.